Entinostat
- Generic Name
- Entinostat
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C21H20N4O3
- CAS Number
- 209783-80-2
- Unique Ingredient Identifier
- 1ZNY4FKK9H
- Background
Entinostat is under investigation for the treatment and other of Volunteers, Breast Cancer, Human Volunteers, and Normal Volunteers. Entinostat has been investigated for the treatment of Non-Small Lung Cancer, Epigenetic Therapy.
- Indication
联合芳香化酶抑制剂用于治疗激素受体（HR）阳性、人类表皮生长因子受体-2（HER-2）阴性，经内分泌治疗复发或进展的局部晚期或转移性乳腺癌患者。
- Associated Conditions
- -
- Associated Therapies
- -
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
- Conditions
- Interventions
- First Posted Date
- 2014-04-16
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 608
- Registration Number
- NCT02115282
- Locations
- 🇺🇸
Eisenhower Medical Center, Rancho Mirage, California, United States
🇺🇸Mercy Cancer Center - Sacramento, Sacramento, California, United States
🇺🇸Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
Azacitidine and Entinostat Before Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-09-05
- Last Posted Date
- 2018-07-27
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT01935947
- Locations
- 🇺🇸
USC Norris Oncology/Hematology-Newport Beach, Newport Beach, California, United States
🇺🇸Medical University of South Carolina, Charleston, South Carolina, United States
🇺🇸Johns Hopkins Bayview Medical Center, Baltimore, Maryland, United States
Phase II Anti-PD1 Epigenetic Therapy Study in NSCLC.
- Conditions
- Interventions
- First Posted Date
- 2013-08-26
- Last Posted Date
- 2024-05-03
- Target Recruit Count
- 143
- Registration Number
- NCT01928576
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸UPMC Cancer Center- Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Sibley Memorial Hospital, Washington, District of Columbia, United States
Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery
- Conditions
- Interventions
- First Posted Date
- 2013-06-26
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT01886573
- Locations
- 🇺🇸
University of New Mexico, Albuquerque, New Mexico, United States
🇺🇸University of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
Study to Assess Food Effect on Pharmacokinetics of Entinostat in Subjects With Breast Cancer or Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2012-05-09
- Last Posted Date
- 2021-11-19
- Lead Sponsor
- Syndax Pharmaceuticals
- Target Recruit Count
- 14
- Registration Number
- NCT01594398
- Locations
- 🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸Florida Cancer Specialists, Sarasota, Florida, United States
🇺🇸Peggy and Charles Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Entinostat, Lapatinib Ditosylate and Trastuzumab in Treating Patients With Locally Recurrent or Distant Relapsed Metastatic Breast Cancer Previously Treated With Trastuzumab Only
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2019-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT01434303
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Entinostat And Imatinib Mesylate In Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2011-06-28
- Last Posted Date
- 2017-08-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 2
- Registration Number
- NCT01383447
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Azacitidine and Entinostat in Treating Patients With Advanced Breast Cancer
- First Posted Date
- 2011-05-09
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT01349959
- Locations
- 🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
🇺🇸Metro Minnesota Community Oncology Research Consortium, Saint Louis Park, Minnesota, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Entinostat and Anastrozole in Treating Postmenopausal Women With TNBC That Can Be Removed by Surgery
- Conditions
- Interventions
- First Posted Date
- 2010-11-04
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- University of Maryland, Baltimore
- Target Recruit Count
- 5
- Registration Number
- NCT01234532
- Locations
- 🇺🇸
University of Maryland Baltimore, Baltimore, Maryland, United States
Azacitidine and Entinostat in Treating Patients With Stage I Non-Small Cell Lung Cancer That Has Been Removed By Surgery
- Conditions
- Interventions
- First Posted Date
- 2010-09-23
- Last Posted Date
- 2019-02-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 13
- Registration Number
- NCT01207726
- Locations
- 🇺🇸
Anne Arundel Medical Center, Annapolis, Maryland, United States
🇺🇸University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.